commonli
seen
generalist
qualifi
patient
sot
includ
symptomat
chronic
condit
congest
heart
failur
chf
chronic
obstruct
lung
diseas
copd
chronic
hepat
chronic
kidney
diseas
ckd
given
preval
chronic
condit
peopl
wait
list
unit
state
sot
waitlist
length
influenc
chang
demand
list
practic
death
rate
donat
rate
alloc
polici
import
awar
demand
sot
increas
fig
sot
recipi
risk
infect
short
long
term
result
higher
morbid
mortal
unlik
vast
major
hematopoiet
cell
transplant
recipi
eventu
immunosuppress
medic
discontinu
sot
patient
requir
lifelong
immunosuppress
therefor
remain
lifelong
increas
risk
infect
avoid
transplant
reject
commonli
use
immunosuppress
regimen
broadli
act
decreas
cellular
humor
immun
reduc
cellular
immun
leav
host
suscept
viral
fungal
intracellular
pathogen
decreas
humor
immun
increas
risk
encapsul
bacteria
sot
recipi
degre
immunosuppress
henc
infecti
risk
tend
decreas
time
never
return
normal
baselin
develop
recurr
chronic
organ
reject
requir
intensif
immunosuppress
regimen
risk
infect
remain
high
usual
immunosuppress
regimen
includ
corticosteroid
calcineurin
inhibitor
antimetabolit
care
decentr
major
transplant
center
even
patient
live
rural
geograph
isol
area
receiv
sot
risk
mani
transplantrel
complic
tend
decreas
month
posttranspl
patient
gener
refer
back
pcpsspecialist
around
month
transplant
henc
subacut
longterm
manag
done
generalist
transplant
center
provid
consult
role
need
transplant
center
provid
patient
primari
physician
packet
transplantspecif
care
guidelin
recommend
monitor
followup
requir
pcp
new
sot
patient
request
inform
transplant
center
box
typic
sign
symptom
infect
mute
immunosuppress
agent
immunocompet
host
sign
symptom
inflamm
rubor
dolor
calor
import
clue
infect
howev
immunosuppress
agent
sot
recipi
receiv
blunt
inflammatori
respons
mechan
prevent
reject
therebi
make
sign
symptom
inflamm
much
subtl
thu
import
pcp
patient
remain
vigil
even
subtl
manifest
infect
common
urgentvisit
concern
lowgrad
fever
new
cough
diarrhea
portend
seriou
infect
articl
review
common
present
symptom
approach
differ
sot
patient
immunocompet
person
time
heighten
awar
medic
cost
grow
resist
antimicrobi
therapi
usual
approach
averagerisk
ambulatori
patient
judici
pragmat
use
diagnost
therapeut
intervent
sever
featur
infect
sot
patient
mandat
differ
approach
use
immunocompet
patient
clinic
present
subtl
multipl
pathogen
may
present
concomitantli
progress
infect
may
rapid
result
gener
comprehens
diagnost
test
earlier
escal
advanc
imag
invas
diagnost
procedur
warrant
sot
patient
although
empir
therapeut
intervent
place
sot
patient
thorough
effort
identifi
character
etiolog
agent
infect
imper
test
use
diagnos
infect
immunocompet
patient
much
less
sensit
sot
patient
exampl
test
reli
host
immun
system
eg
serolog
may
less
sensit
direct
detect
pathogen
although
serolog
test
help
identifi
latent
infect
antibodi
develop
acut
infect
may
delay
never
develop
immunosuppress
patient
instead
direct
detect
pathogen
use
cultur
polymeras
chain
reaction
pcr
forth
optim
specimen
prefer
add
complex
sot
patient
like
immunocompet
patient
rapid
progress
infect
lack
appropri
immun
respons
exampl
pneumonia
safe
treat
ambulatori
set
immunocompet
patient
often
result
hospit
sot
patient
sot
patient
like
multipl
pathogen
resist
pattern
complic
choic
antimicrobi
therapi
earli
involv
infecti
diseas
specialist
may
warrant
pcp
familiar
timelin
suscept
infect
gener
intens
immunosuppress
decreas
time
transplant
result
risk
seriou
opportunist
infect
tend
decreas
time
howev
episod
reject
occur
immunosuppress
medic
intensifi
patient
becom
vulner
opportunist
infect
might
typic
seen
earlier
period
posttranspl
first
month
transplant
vulner
time
nosocomi
infect
multidrugresist
organ
includ
relat
complic
surgeri
nosocomi
infect
may
relat
transplant
surgeri
exposur
hospit
environ
mani
infect
result
venou
urinari
catheter
well
intub
sot
patient
aggress
treat
known
infect
transplant
given
risk
immunosuppress
protocol
exist
screen
donor
infect
short
time
frame
necessit
limit
diagnost
test
although
serolog
test
viral
hepat
human
immunodefici
viru
hiv
herpesvirus
microbiolog
test
blood
urin
cultur
identifi
activ
bacteri
fungal
infect
donorrel
infect
well
describ
first
posttranspl
month
bacteri
fungal
infect
common
viral
infect
often
nosocomi
pathogen
drugresist
strain
sot
patient
time
frame
typic
still
direct
care
transplant
center
effect
immunosuppress
medic
typic
manifest
month
opportunist
infect
tend
common
donoracquir
condit
reactiv
recipi
infect
hepat
b
c
apt
infect
patient
first
month
month
posttranspl
go
well
immunosuppress
typic
taper
patient
leav
direct
care
transplant
program
patient
receiv
prophylaxi
pneumocysti
jiroveci
pneumonia
pjp
trimethoprimsulfamethoxazol
dapson
monthli
inhal
pentamidin
cytomegaloviru
cmv
commonli
valganciclovir
reactiv
latent
infect
occur
time
period
includ
mycobacterium
tuberculosi
strongyloid
stercorali
sot
patient
suscept
period
endem
mycos
includ
coccidioid
histoplasma
blastomyc
cryptococcu
prophylact
medic
typic
discontinu
month
transplant
need
prophylaxi
diminish
time
sot
patient
alway
suscept
typic
communityacquir
viral
bacteri
infect
concern
rais
month
posttranspl
stabl
sot
patient
reduc
dose
immunosuppress
therefor
decreas
risk
opportunist
infect
cmv
epsteinbarr
viru
herp
simplex
viru
hepat
virus
remain
concern
commonli
sot
patient
infect
season
respiratori
gastrointestin
virus
communityacquir
pneumonia
urinari
tract
infect
period
patient
experi
allograft
reject
dose
immunosuppress
medic
increas
requir
higher
level
immunosuppress
risk
opportunist
infect
may
high
posttranspl
period
would
includ
increas
risk
pjp
nocardia
varicella
aspergillu
fig
infecti
diseas
societi
america
idsa
guidelin
recommend
clinician
consid
influenza
patient
acut
onset
fever
respiratori
symptom
influenza
season
idsa
uniqu
diagnost
algorithm
immunosuppress
patient
outsid
influenza
season
warn
chronic
illimmunosuppress
patient
could
present
atyp
sever
consequ
infect
influenza
otherwis
healthi
patient
forgo
diagnost
test
treat
empir
present
care
man
year
post
orthotop
liver
transplant
present
clinic
januari
day
rhinorrhea
mild
sore
throat
dri
cough
mild
headach
chill
ro
neg
pleurisi
dyspnea
posit
fatigu
vital
sign
vs
temperatur
c
heart
rate
hr
beatsmin
blood
pressur
bp
mm
hg
respiratori
rate
rr
breathsmin
oxygen
satur
sat
examin
show
clear
nasal
secret
mild
pharyng
erythema
adenopathi
lung
clear
auscult
bilater
transplant
liver
nontend
palpat
hydrat
oral
urin
without
difficulti
influenza
vaccin
month
prior
within
hour
onset
symptom
sot
patient
approach
differ
although
rate
influenza
infect
sot
patient
appear
similar
gener
popul
sot
vs
gener
popul
sever
infect
higher
type
organ
transplant
may
influenc
risk
complic
lung
transplant
recipi
vulner
follow
liver
kidney
transplant
patient
wherea
healthi
patient
typic
shed
viru
day
prior
week
follow
onset
symptom
sot
patient
infecti
week
month
inabl
clear
viru
like
present
atyp
symptom
includ
lowgrad
fever
sot
patient
influenza
present
fever
henc
symptom
rhinorrhea
dri
cough
sore
throat
gastrointestin
symptom
stomach
upset
diarrhea
commonli
seen
noninfluenza
respiratori
gastrointestin
viral
infect
may
present
symptom
influenza
fever
present
set
symptom
upper
respiratori
tract
infect
predict
sign
influenza
sot
patient
sot
patient
prone
develop
lower
respiratori
tract
infect
includ
influenza
pneumonia
hospit
sot
patient
secondari
bacteri
pneumonia
streptococcu
staphylococcu
hospit
sot
patient
bacteri
superinfect
extrarespiratori
manifest
central
nervou
system
myocardi
involv
result
sot
patient
may
requir
hospit
aggress
manag
influenza
infect
commonli
immunocompet
patient
wherea
empir
therapi
support
therapi
alon
accept
mani
otherwis
healthi
ambulatori
patient
sot
patient
benefit
specif
identif
pathogen
immunocompet
patient
test
soon
symptom
begin
ideal
within
less
day
howev
regardless
time
symptom
onset
appropri
test
sot
patient
influenza
suspicion
aris
wherea
nasopharyng
wash
aspir
superior
immunocompet
patient
upper
lower
respiratori
tract
specimen
help
sot
patient
appropri
workup
transplant
patient
suspect
influenza
rapid
antigen
test
limit
sensit
diagnosi
influenza
neg
test
exclud
diagnosi
sensit
test
respiratori
viru
pcr
panel
becom
gold
standard
mani
laboratori
test
appropri
use
symptomat
patient
caus
confus
identifi
multipl
virus
asymptomat
patient
make
difficult
determin
identifi
virus
pathogen
patient
lower
respiratori
tract
symptom
clinic
radiograph
evid
lower
tract
infect
undergo
bronchoscopi
test
inform
test
reader
advis
visit
season
flu
web
site
center
diseas
control
prevent
http
wwwcdcgovfluprofessionalsdiagnosislabprocedureshtm
increas
resist
pattern
inhibitor
amantadin
influenza
neuraminidas
inhibitor
oral
oseltamivir
inhal
zanamivir
consid
firstlin
therapi
optim
durat
therapi
well
defin
immunocompet
individu
typic
cours
day
howev
sot
patient
continu
shed
viru
longer
durat
activ
treatment
day
weekli
pcr
monitor
consid
given
higher
rate
bacteri
superinfect
coinfect
antibiot
consid
especi
sot
patient
lower
respiratori
infect
symptom
await
result
diagnost
studi
best
way
handl
influenza
vaccin
transplant
patient
sot
patient
vaccin
inactiv
influenza
vaccin
transplant
controversi
optim
time
vaccin
posttranspl
prudent
approach
vaccin
sot
patient
soon
season
vaccin
avail
influenza
season
efficaci
vaccin
may
lower
sot
patient
immunocompet
patient
appear
safe
one
studi
found
popul
sot
patient
diagnos
influenza
receiv
vaccin
none
patient
protect
level
antibodi
influenza
time
admiss
studi
show
influenza
vaccin
decreas
risk
associ
pneumonia
rel
risk
comparison
sot
patient
immun
evid
addit
benefit
gain
highdos
vaccin
intraderm
inocul
live
attenu
nasal
vaccin
contraind
immunocompromis
person
includ
receiv
sot
evid
show
increas
risk
graft
reject
failur
influenza
vaccin
communityacquir
pneumonia
cap
sot
patient
common
time
higher
incid
immunocompet
individu
danger
mortal
rate
canadian
casecontrol
studi
found
immunosuppress
medic
increas
risk
cap
odd
ratio
despit
uniqu
higher
risk
face
sot
patient
idsa
american
thorac
societi
at
specif
consid
immunosuppress
patient
consensu
guidelin
cap
rather
guidelin
address
cap
separ
guidelin
address
nosocomi
pneumonia
recent
hospit
institut
set
patient
present
posttranspl
period
increas
risk
opportunist
infect
given
effect
longer
durat
higher
dose
immunosuppress
medic
viral
infect
cmv
respiratori
virus
caus
primari
lung
infect
time
also
complic
matter
decreas
immun
increas
risk
opportunist
infect
aspergillu
fumigatu
pjp
woman
month
statu
post
livingrel
kidney
transplant
present
clinic
reestablish
care
transplant
report
day
subject
fever
nonproduct
cough
rhinorrhea
sore
throat
nausea
vomit
diarrhea
bodi
ach
anorexia
mild
night
sweat
mani
wellwish
home
sinc
return
suspect
could
infecti
exposur
vs
c
hr
bp
rr
sat
room
air
examin
speak
full
sentenc
look
tire
scatter
shoddi
cervic
adenopathi
nuchal
rigid
scatter
inspiratori
crackl
bilater
wheez
lung
equal
reson
percuss
heart
regular
without
murmur
reassur
soft
abdomin
examin
transplant
kidney
nontend
palpat
at
idsa
recommend
use
assess
tool
pneumonia
sever
determin
appropri
care
set
ambulatori
inpati
icu
recommend
tool
give
point
confus
uremia
respiratori
rate
greater
blood
pressur
less
mm
hg
age
older
score
greater
equal
spur
provid
consid
hospit
patient
pneumonia
sever
index
psi
recommend
tool
initi
element
assess
patient
element
risk
stratifi
higherrisk
class
correl
mortal
risk
psi
higher
discriminatori
power
accur
lowerrisk
patient
neither
tool
specif
consid
immunosuppress
sot
risk
factor
sever
diseas
henc
import
pcp
use
tool
caution
sot
patient
current
guidelin
recommend
tool
use
supplement
data
physician
determin
patient
global
risk
primari
determin
treatment
plan
sot
patient
lower
respiratori
symptom
cough
dyspnea
increas
respiratori
rate
fever
test
includ
complet
blood
count
chemistri
panel
blood
cultur
sputum
cultur
chest
radiograph
although
chest
radiograph
lower
sensit
immunosuppress
peopl
pattern
diseas
radiographi
still
help
focal
airspac
diseas
correl
bacteri
mycobacteri
pneumonia
multifoc
airspac
diseas
nodular
infiltr
much
broader
differenti
discuss
earlier
diffus
interstiti
pattern
concern
pneumocysti
viral
infect
immunocompromis
patient
pulmonari
infiltr
chest
ct
scan
bronchoscopi
clearli
shown
benefit
distinguish
among
infecti
noninfecti
caus
consensu
guidelin
recommend
empir
treatment
institut
tailor
antibiot
choic
reflect
resist
commun
pcp
delay
empir
therapi
wait
test
usual
choic
respiratori
fluoroquinolon
macrolid
broaderspectrum
blactam
macrolid
also
reason
empir
therapi
sot
patient
depend
clinic
present
sever
score
reliabl
level
home
support
patient
treat
outpati
close
followup
wherea
other
need
manag
inpati
set
hospit
immunosuppress
sot
patient
put
risk
nosocomi
infect
import
consider
earli
consult
pulmonari
infecti
diseas
specialist
close
followup
rapid
escal
intens
diagnost
therapeut
effort
depend
respons
appropri
regard
followup
patient
highestrisk
time
frame
opportunist
infect
nodular
infiltr
chest
radiograph
confer
broader
rang
possibl
higherrisk
situat
infecti
diseas
consult
initi
well
hospit
intensifi
diagnost
therapeut
intervent
typic
recommend
regimen
cap
requir
hospit
ceftriaxon
azithromycin
respiratori
fluoroquinolon
would
activ
caus
patient
pneumonia
nocardia
diagnos
gram
stain
bead
branch
filament
gramposit
rod
cultur
bronchial
alveolar
lavag
bal
sampl
invas
procedur
often
necessari
make
diagnosi
pulmonari
nocardosi
one
studi
nocardia
soilborn
bacterium
commonli
present
opportunist
infect
immunosuppress
patient
although
caus
selflimit
indol
diseas
immunocompet
patient
sot
patient
particularli
vulner
tcell
immun
suppress
often
corticosteroid
dose
higher
nocardia
propens
dissemin
site
brain
bone
skin
patient
care
clinic
assess
complic
imag
clinic
appropri
primari
treatment
typic
sulfamethoxazolebas
antibiot
patient
evid
dissemin
outsid
lung
treat
imipenem
initi
given
sulfamethoxazol
allergi
convert
linezolid
oral
month
diarrhea
common
symptom
gener
sot
popul
noninfecti
infecti
caus
preval
morbid
mortal
suscept
immunocompromis
sot
patient
much
higher
sot
patient
present
infecti
caus
diarrhea
acut
onset
chronic
present
differenti
diagnosi
favor
infecti
caus
medic
side
effect
set
prolong
immunosuppress
posttranspl
lymphoprolif
diseas
ptld
consid
unlik
stem
cell
transplant
recipi
graftversushost
diseas
uncommon
reason
diarrhea
follow
solid
organ
transplant
cmv
c
difficil
bacteri
pathogen
common
infecti
caus
parasit
infect
less
common
tabl
c
difficileassoci
diarrhea
cdad
common
nosocomi
antibioticassoci
diarrhea
sot
popul
gener
popul
worri
risk
factor
hospit
gastrointestin
surgeri
advanc
age
uremia
multipl
comorbid
case
cdad
sot
patient
occur
first
month
owe
associ
risk
factor
prolong
hospit
prolong
woman
year
post
liver
transplant
autoimmun
hepat
present
wateri
profus
diarrhea
day
result
lb
kg
unintent
weight
loss
report
nausea
vomit
blood
stool
tenesmu
lowgrad
fever
recent
travel
chang
medic
unusu
riski
food
ingest
sexual
behavior
howev
question
girlscout
leader
daughter
group
recent
day
outing
local
water
park
examin
tire
without
jaundic
vs
c
hr
bp
abdomin
examin
minim
tender
without
guard
rigid
liver
nontend
examin
none
indic
treat
support
therapi
blood
sever
vs
abnorm
b
ova
parasit
stool
sampl
c
enter
pathogen
stool
cultur
enter
pathogen
clostridia
difficil
giardia
cryptosporidium
isospora
cyclospora
correct
answer
pagalilauan
limay
antibiot
exposur
intens
immunosuppress
lateonset
cdad
sot
happen
month
year
transplant
associ
intensif
immunosuppress
address
reject
antibiot
exposur
present
vari
mild
diarrhea
lifethreaten
sepsi
prospect
canadian
studi
sot
patient
found
incid
cdad
increas
intervent
decreas
studi
show
cdad
result
graft
loss
colectomi
death
like
white
blood
cell
count
greater
find
pancol
ct
scan
presenc
confer
increas
risk
complic
event
patient
diseas
progress
despit
time
appropri
antimicrobi
therapi
pcp
aggress
approach
diagnosi
treatment
sot
patient
suspect
cdad
low
threshold
hospit
sot
patient
expedit
care
recommend
diagnost
test
initi
treatment
acut
diarrhea
includ
c
difficil
previous
publish
idsa
guidelin
specif
consid
immunosuppress
diarrhea
last
day
howev
sot
patient
higher
risk
immunocompet
popul
acut
diarrhea
regardless
durat
provid
high
suspicion
bacteri
viral
parasit
caus
uniqu
risk
sot
chronic
immunosuppress
medic
commonli
caus
diarrhea
risk
exposur
antibiot
make
find
diagnosi
complex
process
endoscopi
biopsi
consid
neg
noninvas
evalu
report
rate
abnorm
colonoscopi
histolog
rang
colonoscopi
find
lead
chang
medic
manag
regard
followup
patient
diagnos
cryptosporidiosi
via
special
stain
pcr
fresh
stool
sampl
support
therapi
antimotil
agent
initi
alongsid
cautiou
reduct
immunosuppress
cryptosporidium
fecalor
transmit
waterborn
protozoan
found
worldwid
includ
unit
state
highli
resist
parasit
whose
oocyst
surviv
day
water
despit
appropri
level
iodin
chlorin
treatment
waterborn
outbreak
cryptosporidiosi
trace
water
park
public
fountain
foodborn
outbreak
also
link
infect
food
handler
unpasteur
appl
cider
persontoperson
contact
describ
daycar
center
wherea
caus
selflimit
mild
diarrhea
gener
popul
children
immunocompromis
peopl
show
cryptosporidium
import
caus
sever
infecti
diarrhea
sot
popul
especi
true
children
sot
recipi
intestin
graft
retrospect
cohort
found
increas
risk
cryptosporidiosi
men
longer
durat
diarrheal
symptom
increas
tacrolimu
tac
level
case
cryptosporidiosi
associ
higher
tac
level
also
correl
selflimit
import
increas
creatinin
box
uti
common
adult
renal
kidneypancrea
kp
transplant
patient
report
pediatr
renal
sot
patient
uti
also
affect
sot
recipi
typic
occur
first
month
posttranspl
owe
inher
risk
urinari
catheter
nonren
sot
patient
risk
woman
histori
renal
transplant
month
ago
histori
recurr
urinari
tract
infect
present
concern
urinari
tract
infect
uti
endors
day
frequenc
urgenc
dysuria
mildli
nauseat
chill
vomit
flank
pain
think
urin
mildli
malodor
cloudi
medic
includ
tacrolimu
prednison
mycophenol
mofetil
amlodipin
trimethoprimsulfamethoxazol
ss
pneumocysti
prophylaxi
vs
c
hr
bp
appear
well
rash
flank
tender
mild
tender
surgic
site
transplant
kidney
suprapub
area
urin
dipstick
posit
leukocyt
esteras
nitrit
addit
send
urinalysi
urin
cultur
treat
empir
correct
answer
c
routin
diagnost
studi
workup
diarrhea
gener
popul
use
sot
patient
etiolog
remain
obscur
symptom
persist
meticul
assess
viral
bacteri
parasit
infect
includ
abdomin
imag
colonoscopi
consid
c
difficil
patient
risk
factor
even
communityacquir
diarrhea
consid
cryptosporidiosi
sot
patient
histori
travel
exposur
water
park
cryptosporidium
shed
oocyst
intermitt
serial
test
separ
day
appropri
provid
ask
specif
cryptosporidium
test
may
includ
standard
ova
parasit
test
immunosuppress
medic
may
caus
diarrhea
monitor
immunosuppress
level
close
proactiv
adjust
dose
avoid
relat
toxic
hand
wash
water
soap
import
prevent
strategi
mani
caus
infecti
diarrhea
rotaviru
noroviru
cryptosporidium
effect
kill
alcoholbas
hand
sanit
factor
includ
femal
gender
increas
age
diabet
renal
kp
transplant
patient
risk
uti
high
first
year
transplant
risk
factor
includ
histori
posttranspl
dialysi
age
femal
gender
factor
may
increas
risk
recurr
uti
includ
ureter
strictur
vesicoureter
reflux
prolong
urinari
catheter
overimmunosuppress
uti
occur
higher
frequenc
increas
morbid
renal
transplant
recipi
studi
mix
convincingli
demonstr
increas
risk
graft
reject
increas
mortal
due
uti
wherea
studi
found
specif
immunosuppress
regimen
intens
immunosuppress
appear
increas
risk
uti
studi
support
notion
uti
opportunist
infect
sot
patient
rather
increas
risk
thought
due
factor
tabl
posttranspl
anatom
chang
effect
defin
uti
renal
transplant
patient
complic
uti
asymptomat
bacteriuria
asb
without
sign
symptom
infect
common
renal
transplant
patient
asb
associ
increas
risk
uti
first
year
signific
controversi
exist
whether
treat
within
time
frame
candiduria
common
affect
renal
transplant
patient
mostli
asymptomat
approach
asymptomat
candiduria
also
controversi
given
pauciti
avail
data
topic
convinc
data
exist
show
graft
surviv
morbid
mortal
improv
treatment
asymptomat
candiduria
kidney
transplant
patient
diagnosi
cystiti
sot
patient
gener
popul
import
caveat
urin
cultur
obtain
sot
patient
given
higher
risk
multidrugresist
bacteri
infect
upper
tract
ie
kidney
allograft
infect
common
kidney
transplant
recipi
pyelonephr
consid
kidney
transplant
patient
signssymptom
cystiti
accompani
fever
bacteremia
increas
creatinin
leukocytosi
chill
paintend
transplant
kidney
mani
transplant
center
use
trimethoprimsulfamethoxazol
prophylaxi
pneumocysti
renal
transplant
patient
first
month
transplant
appear
also
decreas
risk
uti
howev
also
associ
breakthrough
infect
caus
trimethoprimsulfamethoxazoleresist
organ
longterm
prophylaxi
shown
decreas
incid
uti
although
grow
resist
trimethoprimsulfamethoxazol
among
gnr
reportedli
set
limit
util
longterm
antibiot
prophylaxi
multicent
prospect
cohort
studi
follow
sot
patient
year
followup
episod
uti
occur
renal
transplant
recipi
vast
major
due
gnr
escherichia
coli
pseudomona
aeruginosa
klebsiella
pneumonia
gram
neg
due
enterococcu
speci
sever
studi
also
identifi
staphylococcu
speci
common
pathogen
renal
sot
patient
alarm
amount
antibiot
resist
observ
onequart
identifi
extendedspectrum
blactamas
resist
esbl
carbapenemresist
klebsiella
pseudomona
aeruginosa
vancomycinresist
enterococcu
increas
frequenc
regard
followup
patient
typic
symptom
cystiti
howev
also
tender
transplant
kidney
fever
suggest
associ
allograft
pyelonephr
inappropri
use
antibiot
effect
lower
uti
eg
nitrofurantoin
fosfomycin
infect
occur
receiv
prophylact
trimethoprimsulfamethoxazol
make
inappropri
empir
therapi
despit
evid
grow
resist
strain
fluoroquinolon
remain
reason
option
empir
therapi
howev
center
high
rate
resist
fluoroquinolon
treatment
broaderspectrum
antibiot
might
appropri
common
pathogen
caus
cystitisgraft
pyelonephr
kidney
transplant
patient
includ
enterococcu
pseudomona
clinic
stabl
sot
patient
without
sign
sepsi
evid
cystiti
appropri
manag
ambulatori
set
howev
concern
graft
pyelonephr
trigger
hospit
evalu
rate
predispos
anatom
abnorm
rel
high
kidney
transplant
recipi
graft
pyelonephr
diagnost
workup
typic
includ
ct
imag
kidney
andor
urolog
evalu
structur
function
abnorm
woman
histori
renal
transplant
year
ago
request
routin
prevent
care
examin
addit
usual
sot
monitor
also
request
booster
shot
vaccin
recommend
past
immun
histori
influenza
last
year
td
year
ago
standard
childhood
vaccin
sot
patient
live
longer
pcp
prepar
address
prevent
care
concern
section
focus
vaccin
prevent
care
issu
uniqu
infecti
risk
face
sot
patient
cover
noninfecti
prevent
care
key
pearl
vaccin
sot
patient
gener
live
vaccin
contraind
posttranspl
immunolog
respons
routin
vaccin
may
diminish
especi
first
month
transplant
situat
suggest
pcp
must
proactiv
patient
chronic
diseas
condit
progress
path
toward
possibl
sot
appropri
live
vaccin
may
includ
measl
mump
rubella
zoster
varicella
administ
pretranspl
patient
immunosuppress
american
societi
transplant
ast
guidelin
recommend
live
vaccin
administ
least
week
transplant
even
inactivatedkil
vaccin
consid
pretranspl
possibl
anticip
better
respons
rate
although
endstag
chronic
ill
necessit
sot
might
associ
reduc
immun
respons
vaccin
immunolog
respons
vaccin
thought
even
suppress
posttranspl
period
three
studi
respons
vaccin
influenza
sot
patient
report
significantli
reduc
protect
titer
comparison
normal
control
lower
respons
correl
sot
patient
combin
immunosuppress
therapi
specif
mycophenol
mofetil
mmf
cyclosporin
implic
given
substanti
morbid
mortal
associ
influenza
immunosuppress
popul
yearli
inactiv
influenza
vaccin
recommend
live
attenu
influenza
vaccin
contraind
sot
patient
sot
patient
higher
risk
gener
popul
invas
pneumococc
infect
although
pneumococc
vaccin
shown
safe
sot
patient
respons
rate
vaccin
reduc
rang
depend
serotyp
measur
major
guidelin
ast
acip
recommend
pneumococc
vaccin
immunosuppress
patient
includ
receiv
solid
organ
transplant
recent
updat
guidelin
incorpor
polysaccharid
conjug
vaccin
recent
publish
sot
patient
advis
follow
week
later
sot
patient
previous
receiv
dose
given
least
year
dose
sot
patient
younger
year
repeat
year
vaccin
age
repeat
year
first
dose
immunolog
respons
tetanu
close
normal
sot
patient
repeat
everi
year
per
idsaacip
guidelin
diphtheria
immun
wane
significantli
even
first
year
current
guidelin
recommend
check
titer
diphtheria
singl
booster
dose
pertussi
vaccin
tdap
given
adult
older
year
human
papilloma
viru
hpv
vaccin
well
studi
sot
patient
live
vaccin
therefor
theoret
safe
posttranspl
popul
indic
hpv
vaccin
similar
nonsot
patient
safe
give
hepat
b
meningococc
h
influenza
b
vaccin
transplant
patient
indic
first
month
sot
immunosuppress
peak
ideal
time
vaccin
administr
immunolog
respons
significantli
diminish
householdoth
close
contact
presum
primari
sourc
mani
import
infect
import
pcp
counsel
sot
patient
famili
close
contact
import
appropri
immun
pcp
add
list
annual
prevent
care
remind
sot
patient
tabl
risk
cervic
cancer
reportedli
increas
immunosuppress
patient
comparison
gener
popul
recommend
unit
state
prevent
task
forc
servic
uspstf
american
colleg
obstetr
gynecolog
yearli
papanicola
smear
pelvic
examin
cervic
cancer
screen
immunosuppress
patient
howev
practic
best
support
peopl
immunosuppress
hiv
infect
evid
hpv
caus
cervic
cancer
excel
increas
risk
cervic
cancer
evidenc
hiv
immunosuppress
extrapol
appli
sot
patient
howev
engel
colleagu
evalu
data
unit
state
registri
sot
patient
found
increas
risk
cervic
cancer
addit
prospect
casecontrol
studi
renal
kp
sot
patient
show
increas
risk
cervic
cancer
sot
patient
despit
emerg
data
immunosuppress
sot
recipi
might
necessarili
increas
risk
cervic
cancer
present
pcp
follow
updat
uspstf
cervic
cancer
screen
guidelin
explicitli
exclud
immunosuppress
patient
lengthen
screen
interv
beyond
year
summari
sot
recipi
need
pcp
familiar
uniqu
need
understand
lifelong
infecti
risk
face
sot
patient
need
lifelong
immunosuppress
medic
fundament
sot
recipi
present
atyp
mute
manifest
infect
savvi
prepar
pcp
keep
care
eye
patient
initi
comprehens
evalu
infecti
etiolog
pcp
work
togeth
local
infecti
diseas
specialist
gener
care
plan
diagnosi
manag
question
